Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CCR5 | P51681 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL737369 | 0.99 | HRH3 (0.42) | HRH3MAPTSMN1; SMN2HTTALDH1A1 | |
| SCHEMBL736647 | 0.99 | HRH3 (0.41) | HRH3MAPTSMN1; SMN2HTTALDH1A1 | |
| SCHEMBL4940466 | 0.97 | MAPT (0.42) | HRH3MAPTSMN1; SMN2HTTALDH1A1 | |
| SCHEMBL737545 | 0.77 | MAPT (0.50) | HRH3MAPTHTTALDH1A1LMNA | |
| SCHEMBL4536337 | 0.77 | OPRM1 (0.52) | KMT2AL3MBTL1 | |
| SCHEMBL4940044 | 0.74 | KDM4E (0.51) | HRH3MAPTSMN1; SMN2HTTALDH1A1 | |
| SCHEMBL735913 | 0.74 | KDM4E (0.48) | HRH3MAPTSMN1; SMN2HTTALDH1A1 | |
| SCHEMBL736957 | 0.73 | KDM4E (0.50) | HRH3MAPTSMN1; SMN2HTTALDH1A1 | |
| SCHEMBL737726 | 0.73 | MAPT (0.48) | HRH3MAPTSMN1; SMN2HTTALDH1A1 | |
| SCHEMBL737638 | 0.72 | RAB9A (0.46) | HRH3MAPTSMN1; SMN2HTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101228127-B | Piperidine derivatives | BANYU PHARMA CO LTD | 2012-05-16 | — | — | CN | disclosed |
| US-8138206-B2 | Piperidine derivative | MSD. K.K. (JP) | 2012-03-20 | — | — | US | disclosed |
| US-20090137576-A1 | Novel Piperidine Derivative | MSD K.K. (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-1892241-A1 | NOVEL PIPERIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-02-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137576-A1 | Novel Piperidine Derivative | HRH4, HRH3, HRH1 | HRH3 2/4885MAPT 4377/4885SMN1; SMN2 4135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.